A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients-Reference-Cited by-同舟云学术

A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients

Published:2002-10 Issue:7 Volume:74 Page:961-966
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:Transplantation

Author:

Offner Gisela,Broyer Michel,Niaudet Patrick,Loirat Chantal,Mentser Mark,Lemire Jacques,Crocker John F. S.,Cochat Pierre,Clark Godfrey,Chodoff Lawrence,Korn Alexander,Hall Michael

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference11 articles.

1. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients

2. REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2

3. PEDIATRIC RENAL TRANSPLANTS—RESULTS WITH SEQUENTIAL IMMUNOSUPPRESSION1,2

4. Non-compliance following renal transplantation in children and adolescents

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab as induction therapy in pediatric kidney transplantation: A single‐center experience in four patients;Pediatric Transplantation;2022-06-02

2. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies;Expert Opinion on Drug Metabolism & Toxicology;2018-06-03

3. Biologic Therapies;Pediatric Allergy: Principles and Practice;2016

4. Immunosuppression for Pediatric Renal Transplantation;Pediatric Nephrology;2015-11-12

5. Immunosuppression for Pediatric Renal Transplantation;Pediatric Nephrology;2015